The full peptide framework for herniated disc and degenerative disc disease: unload the spine (retatrutide), repair the avascular tissue (BPC-157 + TB-500), calm the neuroinflammatory nerve pain (ARA-290), and don't suppress the inflammation that clears a herniation. Regeneration vs degeneration, every article embedded.
A disc stack is two or more compounds taken at the same time for a worn or bulging spinal disc — most often BPC-157 with TB-500, sometimes with ARA-290 added for the leg pain, sometimes alongside a weight-loss drug. Each compound is aimed at a different step in how a disc fails.
Underneath all of it is one arithmetic. A disc is being broken down at some speed and built back at some other speed, and how your back feels in six months is decided by which of the two is faster. Every single thing on the list below — walking, smoking, a needle, a tablet, a vial — moves one of those two speeds by some amount. What decides your outcome is not any one of those amounts. It is the sum.
That sum is what almost nothing has been measured on. Nobody with a bad disc runs one variable. They are walking or not walking, sleeping six hours or eight, carrying an extra thirty pounds or not, taking ibuprofen daily or not, and injecting one compound or three — all in the same week. The individual numbers below are real and mostly good. The combined numbers, with three exceptions, do not exist, and where they do exist one of them came back negative.
A worn disc is two speeds, and the slow one is the blood supply
The disc is the largest structure in the body with almost no blood supply of its own. Small vessels reach the outermost fibres of the tough outer ring and stop there; the soft centre is fed by fluid seeping through the bone above and below it. Every repair process in the body runs on blood delivery, so the disc rebuilds more slowly than any other load-bearing tissue you own.
That does not mean the rebuild side loses. Pooled across eleven cohort studies of people managed without surgery, 66.66% of herniated discs shrank on their own (95% CI 51% to 69%). In the United Kingdom subset the figure was 82.94%; in the Japanese subset, 62.58%.
The shrinking is done by immune cells that treat the displaced fragment as foreign material, digest it, and bring new blood vessels in behind them to carry the debris away.
Two things follow from that pair of facts, and they set up everything else. First, the rebuild side already wins about two times in three with nobody doing anything. Second, the mechanism it wins by is inflammation plus new blood vessel growth — which is precisely the mechanism a daily anti-inflammatory tablet is designed to shut down.
Genetics puts a number on each thing that wears a disc down
Observational studies of back pain are badly confounded: people who smoke also move less, weigh more and sleep worse, so an association tells you almost nothing about direction. Mendelian randomisation gets around that by using inherited gene variants as the exposure — you are assigned your variants at conception, before any lifestyle exists, so the arrow can only point one way.
A 2026 synthesis pooled twenty such studies in people against disc degeneration and put an odds ratio on each factor. An odds ratio of 1.26 means roughly a 26% higher chance of the outcome per unit of the exposure.
What moves the breakdown speed
Odds of disc degeneration
How to move it
Time spent sitting watching television
1.78 (1.52–2.08)
Stand up and walk; this is the largest lifestyle number in the set
The body-mass row has a second, condition-specific measurement behind it. A meta-analysis of observational studies in people found overweight raised the odds of nerve-root leg pain by 1.23 and obesity by 1.40 — the same direction as the genetic estimate, in the exact symptom most people with a disc actually have.
Read the television row again, because it is the one nobody talks about. Genetically predicted television time carried a larger effect on disc degeneration than smoking, weight, blood fats and diabetes. Sitting still is the biggest modifiable factor in the whole causal set.
On stopping smoking, the honest answer has a limit in it. Rats exposed to cigarette smoke for eight weeks developed cracked, torn, misaligned outer rings and fibrous tissue in the soft centre. After they stopped, the degeneration stopped getting worse and the soft centre regained some of its gel-like material. The physical misalignment of the outer ring did not come back, and the inflammatory signal IL-1beta was still raised eight weeks after the last cigarette.
So stopping smoking halts the slide and buys back part of the chemistry, and does not undo the structural damage already done. That distinction — halting versus reversing — applies to almost every item on this page.
Two more entries on the breakdown side, both self-inflicted by treatment rather than by lifestyle.
Repeated steroid injections into the spine cost bone. Three thousand injected patients were compared with three thousand matched controls; each successive injection raised the risk of a vertebral fracture by a factor of 1.21 (95% CI 1.08 to 1.30). One injection is a small bill. A course of six is a compounding one.
Months of daily anti-inflammatories buy less pain relief than most people assume and work against the clearance mechanism described above. Pooled across 32 trials and 5,356 people with acute back pain, the drugs beat placebo by 7.29 points on a 0–100 pain scale — a difference the Cochrane reviewers called small and probably not clinically relevant.
Walking is the only item on this page with a hazard ratio behind it
WalkBack randomised 701 Australian adults who had just recovered from a back pain episode into either an individualised, progressive walking programme with six physiotherapist sessions over six months, or no treatment at all. The walking group went a median 208 days before their next activity-limiting episode (95% CI 149–295). The control group went 112 days (89–140). The hazard ratio was 0.72 (95% CI 0.60–0.85, p=0.0002) — meaning that at any given moment, a walker's chance of the pain returning was 28% lower.
Two details in that trial matter for anyone assembling a combination. It cost AU$7,802 per quality-adjusted life-year, which made it cost-effective with 94% probability. And it was not free of harm: lower-limb adverse events ran 100 in the walking group against 54 in the control group.
For pain that is already chronic rather than recurring, structured exercise pooled across 249 randomised trials in people produced roughly a 15-point improvement on a 0–100 scale against no treatment or usual care — about double what an anti-inflammatory delivers for acute pain, and roughly five times what one delivers for chronic pain.
That is the whole evidence-based core of a disc recovery plan, and it is walking and loading. Everything else on this page is added on top of it, and nothing else on this page has a number that comes close.
Three things sold as the raw material for the rebuild were tested and did nothing
The intuition that a rebuilding tissue needs feeding is reasonable. The intuition has been tested three times and lost three times, and a page that skipped that would be selling something.
Collagen. Thirty-nine recreationally active men took either 15 g of collagen peptides daily or a placebo through 15 weeks of supervised lower-body resistance training. Both groups gained tendon stiffness (+17.3% collagen, +20.9% placebo) and Young's modulus (+17.8% versus +20.6%). Between the groups, nothing: no difference on any tendon measure, with p-values between 0.365 and 0.877. The training built the tendon. The powder added nothing detectable.
Vitamin D. Ten randomised trials in people with chronic low back pain, pooled: standardised mean difference −0.130 (95% CI −0.260 to 0.000), which touches zero. Long-term dosing did not help either, and neither did the active forms. Baseline vitamin D status made no difference to the result.
Weight loss on its own, once exercise is already in place. Across 22 trials and 3,602 people, weight-loss interventions beat minimal care on pain (SMD −0.54) — but head to head against exercise alone, in four trials and 673 people, weight loss was no better (SMD −0.13, 95% CI −0.40 to 0.14). The credibility of the whole body of evidence was rated very low.
That last result is a compounding finding, not a single-factor one, and it is the first of only three real interaction measurements on this entire page. Weight loss and exercise are not additive in the way the arithmetic of the two-speeds model would suggest. They overlap. Buying both does not buy you twice.
Each peptide is aimed at a different step, and none has been put near a disc
BPC-157 is a fifteen-amino-acid chain based on a sequence found in human stomach fluid. In rats it raises VEGF, the signal that grows new blood vessels into damaged tissue, and drives connective-tissue cells to move into an injury and rebuild it. A cut rat Achilles tendon treated with it came back mechanically stronger than an untreated one.
TB-500 is a seven-amino-acid fragment of a larger natural protein, thymosin beta-4. In animals it acts on cell movement and on the organisation of collagen laid down in a healing wound. The molecule in the vial and the molecule in most of the published research are not the same thing, which is covered in full on its own page.
The reason a nerve compound is in a disc stack at all is that a large share of the pain is chemical rather than mechanical. Material leaking from a torn disc releases TNF-alpha and IL-1beta onto the nerve root, and those two signals are the ones tied to both the ongoing breakdown of the disc and the pain itself.
ARA-290 is the only one of the three with randomised human evidence of any kind. In a 28-day phase 2b trial, 64 people with sarcoidosis-related small nerve fibre loss and nerve pain took 1, 4 or 8 mg a day or placebo. At 4 mg the corneal nerve fibre area rose by 697 µm² over placebo (95% CI 159–1,236, p=0.012), and regenerating skin nerve fibres rose too (p=0.035). Pain improved in every group including placebo; the placebo-corrected pain difference in the moderate-to-severe subgroup did not reach significance (p=0.157).
Read that carefully, because it is the strongest human result any compound in this stack has, and it is about a nerve in an eye of a person with sarcoidosis. Nobody has run ARA-290 against a nerve root squeezed by a disc. Human evidence in one tissue and one disease does not transfer to another by argument.
Retatrutide is not a disc compound at all. It is a weight-loss drug, and its only relevance here runs through the body-mass row of the table above: less load on the column, no direct action on disc tissue.
The one experiment that tested the pair found no bonus for taking both
This is the single most important result on this page, and it is the one that the phrase "the repair pair" was invented before anybody had.
In 2026, 32 male Sprague-Dawley rats, each about 330 g, had their Achilles tendon cut and repaired, then were split into four groups of eight: control, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, and both together. Everything was injected into the belly, daily, for four weeks.
Results, arm by arm:
Arm
Load to failure
Tissue architecture score
Verdict
Control
baseline
baseline
—
BPC-157 alone
higher, not statistically significant
numerically better, not significant
signal without proof
TB-500 alone
higher, significant (p<0.05)
Bonar p=0.016, Movin p=0.017
the only arm that moved the mechanical number
Both together
not significantly better than either alone
Movin p=0.040
no bonus for the second compound
The authors' own sentence: "Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone."
Their proposed explanation is that the two compounds converge on the same downstream machinery, so the second one has nothing left to add. They flag it as a hypothesis needing confirmation.
Now negate it properly, because a single result does not settle a question in either direction. Eight rats per arm is small. An additive effect of, say, 15% would very likely be missed at that sample size. The endpoint was a tendon at four weeks, not a disc at six months. The route was into the belly, which is not how anybody takes either compound. And no dose-response work was done, so a different ratio of the two might behave differently. What the experiment establishes is narrow and real: at these doses, in this tissue, on these endpoints, the pair did not beat the better single compound. What it does not establish is that combining them is pointless everywhere.
The claim it does damage to is specific. Anyone who tells you the two compounds are synergistic is describing a mechanism, not a measurement. The measurement exists, it was taken in 2026, and it came back flat.
Six real combinations, side by side
Nobody chooses one row of the tables above. They choose a whole column of behaviour. Here are six combinations a person with a bad disc actually ends up in, with what is known about each part, what is known about the parts in combination, and where the interaction has never been measured.
The combination
What each part is measured at, alone
What is measured about the combination
Never measured
A. Walking 25 min/day + adequate protein + BPC-157 + TB-500
Walking: hazard ratio 0.72, 701 people, HUMAN. Protein/collagen: no tendon effect over placebo in 39 men, HUMAN. BPC-157: rat tendon repair, ANIMAL. TB-500: rat tendon repair, ANIMAL
The two peptides together: no benefit beyond either alone in 32 rats, ANIMAL
Walking with either peptide, in any species. Any of it in a human disc
B. Smoking + no movement + repeated steroid injections + daily anti-inflammatories
Smoking: odds 1.22, HUMAN. Sitting: odds 1.78, HUMAN. Each steroid injection: 1.21× fracture risk, HUMAN. Anti-inflammatories: 7.29/100 points of pain relief and suppression of the clearance mechanism, HUMAN
Nothing. Not one study has combined these four
Everything. This is the most common real-world combination and the least studied
C. Walking alone, nothing else changed
Hazard ratio 0.72 for recurrence; ~15/100 points for chronic pain across 249 trials, HUMAN
This is the measured baseline every other row should be compared against
—
D. Both peptides, no change to movement or weight
Rat tendon data only, ANIMAL
The pair, in rats: no additive benefit, ANIMAL
Whether peptides do anything at all when the load driving the damage is unchanged
E. Weight loss on a GLP-1 drug + walking, no peptides
Weight: odds 1.26 per unit of body mass index, HUMAN. Walking: hazard ratio 0.72, HUMAN
Weight loss versus exercise alone, head to head: no added benefit, 4 trials, 673 people, HUMAN
Retatrutide specifically — a 586-person trial is running and reports in 2027
F. Everything: walking + weight loss + BPC-157 + TB-500 + ARA-290
Each part as above; ARA-290 has 64-person HUMAN data in a different disease
Nothing whatsoever
The entire combination. No study in any species has given three of these compounds together
Read column three. Across six combinations, the total measured interaction evidence is three findings: weight loss adds nothing on top of exercise in people, the two peptides add nothing on top of each other in rats, and nothing else has been looked at.
The interactions nobody has measured, written down so the holes are visible
Naming a gap is a finding. These are the specific pairs and triples that a person assembling a stack is implicitly betting on, with no measurement behind them:
BPC-157 combined with any form of exercise, in any species.
Either peptide combined with an anti-inflammatory drug — which matters, because the drug suppresses the same new-blood-vessel step the peptide is proposed to drive. Rats given BPC-157 alongside diclofenac had less gut damage, but nobody measured the tendon.
ARA-290 combined with either of the other two, in any species.
Any of the three during active shrinking of a herniation, where the body's own immune clean-up is already running.
Weight loss combined with either peptide.
All three peptides together, which is what the popular stack actually is.
Any of it against the 66.66% background rate of the disc fixing itself. This is the sharpest hole: without a control arm, a person who improves on a stack cannot tell whether the stack did it or whether they were in the two-thirds.
Every claim above, against the thing that would break it
A claim counts as established only after it has survived its own negation. Here is each substantive claim on this page put against what would falsify it, and whether that test has been run.
Claim
Tier
What would break it
Has that been tested?
Most herniations shrink without treatment
HUMAN
A cohort where imaging shows no change in most people
Tested repeatedly; 11 cohorts pooled at 66.66%
Walking lowers the recurrence rate
HUMAN
A randomised trial where the walking arm relapses as fast as controls
Tested; 701 people; walking arm went 96 days longer
Sitting is the largest modifiable driver of degeneration
HUMAN
A causal-genetic study putting television time below smoking or weight
Tested in 20 pooled studies; television time came out highest at 1.78
Supplying raw material speeds tissue rebuilding
HUMAN
A trial where collagen plus training beats training alone
Tested; 39 men, 15 weeks, no between-group difference
Vitamin D helps chronic back pain
HUMAN
A pooled result whose confidence interval excludes zero
Tested; 10 trials; interval touches zero
Weight loss adds to exercise
HUMAN
A head-to-head trial where the combined arm beats exercise alone
Tested; 4 trials, 673 people; no added benefit
BPC-157 and TB-500 are synergistic
ANIMAL
An experiment where the combined arm beats both single arms
Tested once, 2026, 32 rats: the combined arm did not beat either alone
BPC-157 rebuilds tendon
ANIMAL
Rat tendons treated with it failing at the same load as controls
Tested; treated tendons failed at higher loads; never tested in a person
ARA-290 regrows nerve fibres
HUMAN
A randomised trial where nerve fibre area does not rise over placebo
Tested; rose 697 µm² over placebo at 4 mg, p=0.012, in sarcoidosis
ARA-290 relieves nerve pain from a squeezed nerve root
—
Any randomised trial in that population
Never run. This claim is untested, not supported
Any peptide here changes a human disc
—
An imaging trial with a placebo arm
Never run in any species
Repeated steroid injections are consequence-free
HUMAN
A matched cohort showing no rise in fracture risk with injection count
Tested; each injection multiplied fracture risk by 1.21
Sleep matters to how a disc feels
HUMAN
A crossover trial where cutting sleep does not change pain thresholds
Tested; 39 volunteers; cutting sleep by 40% raised pain sensitivity, with no change in inflammatory blood markers
One row deserves adding, because it is the only human evidence that a degenerated disc responds to anything regenerative at all. Pooled across trials of stem cell injection into painful degenerated discs, pain and disability scores improved — small studies, early, and the only positive human regeneration signal that exists for this tissue.
The three rows with no tier are the honest edge of this subject. They are not weak evidence. They are absence of evidence, and they sit in a table rather than in the headline because eleven of the fourteen rows above them have real numbers.
Fifteen first-person accounts on X, all self-reported, none verified, none from any trial. Ten of them ran two or more compounds together for a spine problem, and five ran BPC-157 on its own. One further account reports harm from the pair at a different site.
Of the ten who stacked, seven reported it helped, two reported partial benefit, and one reported none.
Three weeks on the pair after an L4-L5 herniation, back on a basketball court against two months last time:
Of the five who ran a single compound, one reported it helped, three reported nothing, and one reported that one compound did nothing for him while a different one worked.
L5/S1 herniation, BPC-157 alone and deliberately unpaired, 90% pain reduction in two weeks:
One compound nothing for a back injury, the other clearing it in five days — which is the closest thing in this entire set to a within-person comparison, and it points at the two compounds not being interchangeable:
Harm — 1 report. Two months of the pair for knees brought slight improvement in the joints, along with badly disrupted sleep and lowered heart-rate variability. Both the sleep and the heart-rate variability went back to normal after stopping.
What fifteen accounts settle, and what they cannot. They cannot compare the stack against a single compound, even though the numbers above look like they do. The stacked group reported a better outcome rate than the single-compound group — 7 of 10 against 1 of 5 — and that difference is worthless as evidence. People who buy three vials have spent more, expect more, and are more likely to post a result. People who describe a null outcome tend to be answering somebody else's thread rather than writing their own. And every single one of these people is running against a background rate where two thirds of herniations resolve regardless.
What the accounts do settle is narrower and still worth having. The reported experience is not uniformly positive: four of fifteen describe no benefit for a spine, and one describes a genuine harm. Timelines that people report cluster at two to six weeks, which is faster than any animal tendon study would predict and is exactly the window in which spontaneous shrinking also happens. Nobody in this set reported a serious adverse event.
Two registry entries that would move a row each, and a third that is only a template
Two entries on ClinicalTrials.gov are marked recruiting and would each convert one row of the tables above from mechanism into measurement. Neither of them is a disc. A third entry is listed below because it circulates as though it were a trial, and it is not one.
Registry ID
What it tests
Size
Primary endpoint
Reports
NCT07035093
Retatrutide in people with obesity or overweight and chronic low back pain, phase 3, Eli Lilly
586
Pain intensity and body weight change, to 72 weeks
Estimated September 2027
NCT07437547
BPC-157 for acute hamstring strain, phase 2, Hudson Biotech
120
Days to unrestricted sport, and MRI injury volume at day 14 under blinded central review
Estimated February 2027
NCT07487363
Not a trial. A record that declares itself a fictional example, written in the style of a TB-500 study of cardiovascular markers in stable arterial disease, phase 1/2, Hudson Biotech
80, stated inside the example
Treatment-emergent adverse events at 12 weeks, stated inside the example
Nothing will ever report
Read the third row against its own record before counting it. The public summary of NCT07487363 opens: "This fictional study is an example of a ClinicalTrials.gov-style record." Its dose field says the levels "are not provided in this public example." It is a demonstration template, and any page citing it as proof that TB-500 is being tested in people is citing a placeholder. Its sponsor, Hudson Biotech, filed eight entries of that shape between 2 and 15 February 2026, one of which is the BPC-157 hamstring entry in the row above it.
The BPC-157 hamstring trial is the one worth watching, because MRI injury volume under blinded review is the first objective tissue measurement of this compound in a person. If it comes back flat, the entire rat literature stops transferring. If it comes back positive, the disc question becomes worth running rather than worth arguing about.
What holds always, what holds never, and what depends on something
Foundational — true with everything else stripped away. The disc has almost no blood supply and rebuilds slowly. Immune cells and new blood vessels are what remove a herniated fragment. Load, weight, sitting time, smoking and blood sugar act on the breakdown speed. Movement acts on the rebuild speed. BPC-157 and TB-500 are proposed to act on the rebuild speed by improving blood vessel growth and connective tissue repair. ARA-290 acts on nerve fibres, not on the disc.
Always true. Two out of three herniations shrink without treatment, so any uncontrolled personal result is uninterpretable. Every steroid injection adds fracture risk in proportion to the count. Any claim about a peptide in a human disc rests on zero measurements in any species.
Never true. No compound named on this page is an approved medicine for a disc anywhere in the world. No published experiment has found a bonus from combining BPC-157 with TB-500 — the one experiment that tested it found none. No trial has combined a peptide with exercise, with weight loss, or with an anti-inflammatory.
Conditional, with the dependency named. Walking lowers recurrence risk by 28% — in adults who have recently recovered from an episode, over six months of a progressive programme with physiotherapist contact, not in someone in acute pain today. Stopping smoking halts further degeneration and partly restores the gel in the soft centre — in rats, over eight weeks, and it does not reverse the structural misalignment. ARA-290 regrows nerve fibres — in 64 people with sarcoidosis, at 4 mg a day for 28 days, measured in the cornea. BPC-157 strengthens a healing tendon — in rats, injected into the belly, at 10 µg/kg/day, measured at four weeks. TB-500 improves tendon architecture and load to failure — in rats, at 60 µg/kg/day, on the same schedule. Weight loss reduces back pain — against minimal care, and not against exercise.
Red-flag symptoms are the exception to everything above and are not a matter of weighing evidence: loss of bladder or bowel control, numbness across the area that would contact a saddle, or weakness that is getting worse are emergencies and need a hospital the same day. Nothing on this page is a dose, a schedule or a recommendation to take anything, and every compound named is unapproved for disc disease. TB-500 and BPC-157 are both banned in tested sport at all times.
66.66%
of herniated discs shrank on their own, pooled across 11 cohort studies of people managed without surgery
0.72
hazard ratio for a new back-pain episode in the walking group against no treatment, 701 adults
208 vs 112
median days before back pain returned, walking programme against no treatment
0
extra benefit measured when BPC-157 and TB-500 were given together instead of alone, 32 rats, 8 per arm
1.78
odds of disc degeneration per unit of genetically predicted television time, the largest lifestyle factor across 20 pooled studies
1.21x
vertebral fracture risk added by each successive epidural steroid injection, 3,000 injected vs 3,000 matched controls
Six weeks of the pair — shoulder and biceps resolved, the disc only partly (anecdotal, X, 2026-07-31)“My lowest disc in the lower back is dried out, almost no fluid left, classic herniated disc... In June I ran BPC-157 and TB-500 for about 6 weeks... After 3-4 weeks it already felt better. Now after the cycle, zero pain in biceps and shoulder. Disc still needs physio and rest, but already much better.”
{
"schema":"http://google-preview.miscsubjects.com/schemas/jarticle.json",
"status":"published",
"slug":"the-disc-stack",
"title":"The Disc Recovery Stack",
"kind":"essay",
"summary":"The full peptide framework for herniated disc and degenerative disc disease: unload the spine (retatrutide), repair the avascular tissue (BPC-157 + TB-500), calm the neuroinflammatory nerve pain (ARA-290), and don't suppress the inflammation that clears a herniation. Regeneration vs degeneration, every article embedded.",
"created":"2026-07-24T17:02:40.823Z",
"body": [
"A disc stack is two or more compounds taken at the same time for a worn or bulging spinal disc — most often BPC-157 with TB-500, sometimes with ARA-290 added for the leg pain, sometimes alongside a weight-loss drug. Each compound is aimed at a different step in how a disc fails.\n\nUnderneath all of it is one arithmetic. A disc is being broken down at some speed and built back at some other speed, and how your back feels in six months is decided by which of the two is faster. Every single thing on the list below — walking, smoking, a needle, a tablet, a vial — moves one of those two speeds by some amount. What decides your outcome is not any one of those amounts. It is the sum.\n\nThat sum is what almost nothing has been measured on. Nobody with a bad disc runs one variable. They are walking or not walking, sleeping six hours or eight, carrying an extra thirty pounds or not, taking ibuprofen daily or not, and injecting one compound or three — all in the same week. The individual numbers below are real and mostly good. The combined numbers, with three exceptions, do not exist, and where they do exist one of them came back negative.\n\n## A worn disc is two speeds, and the slow one is the blood supply\n\nThe disc is the largest structure in the body with almost no blood supply of its own. Small vessels reach the outermost fibres of the tough outer ring and stop there; the soft centre is fed by fluid seeping through the bone above and below it. Every repair process in the body runs on blood delivery, so the disc rebuilds more slowly than any other load-bearing tissue you own.",
{
"type":"source",
"id":"s1"
},
"That does not mean the rebuild side loses. Pooled across eleven cohort studies of people managed without surgery, 66.66% of herniated discs shrank on their own (95% CI 51% to 69%). In the United Kingdom subset the figure was 82.94%; in the Japanese subset, 62.58%.",
{
"type":"source",
"id":"s2"
},
"The shrinking is done by immune cells that treat the displaced fragment as foreign material, digest it, and bring new blood vessels in behind them to carry the debris away.",
{
"type":"source",
"id":"s3"
},
"Two things follow from that pair of facts, and they set up everything else. First, the rebuild side already wins about two times in three with nobody doing anything. Second, the mechanism it wins by is inflammation plus new blood vessel growth — which is precisely the mechanism a daily anti-inflammatory tablet is designed to shut down.\n\n![[degenerative-disc-disease]]\n\n## Genetics puts a number on each thing that wears a disc down\n\nObservational studies of back pain are badly confounded: people who smoke also move less, weigh more and sleep worse, so an association tells you almost nothing about direction. Mendelian randomisation gets around that by using inherited gene variants as the exposure — you are assigned your variants at conception, before any lifestyle exists, so the arrow can only point one way.\n\nA 2026 synthesis pooled twenty such studies in people against disc degeneration and put an odds ratio on each factor. An odds ratio of 1.26 means roughly a 26% higher chance of the outcome per unit of the exposure.\n\n| What moves the breakdown speed | Odds of disc degeneration | How to move it |\n|---|---|---|\n| Time spent sitting watching television | 1.78 (1.52–2.08) | Stand up and walk; this is the largest lifestyle number in the set |\n| Body mass index | 1.26 (1.14–1.38) | Weight loss by any route |\n| Waist circumference | 1.26 (1.04–1.53) | Same lever, measured at the belly |\n| Smoking, ever having started | 1.22 (1.12–1.33) | Stopping — with a caveat below |\n| Triglycerides in the blood | 1.08 (1.03–1.13) | Diet, weight loss, movement |\n| Type 2 diabetes | 1.05 (1.03–1.07) | Glucose control |\n| Higher bone density | 1.20 (1.15–1.25) | Not a lever — you would not lower it on purpose |",
{
"type":"source",
"id":"s8"
},
"The body-mass row has a second, condition-specific measurement behind it. A meta-analysis of observational studies in people found overweight raised the odds of nerve-root leg pain by 1.23 and obesity by 1.40 — the same direction as the genetic estimate, in the exact symptom most people with a disc actually have.",
{
"type":"source",
"id":"s4"
},
"Read the television row again, because it is the one nobody talks about. Genetically predicted television time carried a larger effect on disc degeneration than smoking, weight, blood fats and diabetes. Sitting still is the biggest modifiable factor in the whole causal set.\n\nOn stopping smoking, the honest answer has a limit in it. Rats exposed to cigarette smoke for eight weeks developed cracked, torn, misaligned outer rings and fibrous tissue in the soft centre. After they stopped, the degeneration stopped getting worse and the soft centre regained some of its gel-like material. The physical misalignment of the outer ring did not come back, and the inflammatory signal IL-1beta was still raised eight weeks after the last cigarette.",
{
"type":"source",
"id":"s17"
},
"So stopping smoking halts the slide and buys back part of the chemistry, and does not undo the structural damage already done. That distinction — halting versus reversing — applies to almost every item on this page.\n\nTwo more entries on the breakdown side, both self-inflicted by treatment rather than by lifestyle.\n\nRepeated steroid injections into the spine cost bone. Three thousand injected patients were compared with three thousand matched controls; each successive injection raised the risk of a vertebral fracture by a factor of 1.21 (95% CI 1.08 to 1.30). One injection is a small bill. A course of six is a compounding one.",
{
"type":"source",
"id":"s14"
},
"Months of daily anti-inflammatories buy less pain relief than most people assume and work against the clearance mechanism described above. Pooled across 32 trials and 5,356 people with acute back pain, the drugs beat placebo by 7.29 points on a 0–100 pain scale — a difference the Cochrane reviewers called small and probably not clinically relevant.",
{
"type":"source",
"id":"s21"
},
"![[bpc-157-vs-nsaids]]\n\n## Walking is the only item on this page with a hazard ratio behind it\n\nWalkBack randomised 701 Australian adults who had just recovered from a back pain episode into either an individualised, progressive walking programme with six physiotherapist sessions over six months, or no treatment at all. The walking group went a median 208 days before their next activity-limiting episode (95% CI 149–295). The control group went 112 days (89–140). The hazard ratio was 0.72 (95% CI 0.60–0.85, p=0.0002) — meaning that at any given moment, a walker's chance of the pain returning was 28% lower.",
{
"type":"source",
"id":"s7"
},
"Two details in that trial matter for anyone assembling a combination. It cost AU$7,802 per quality-adjusted life-year, which made it cost-effective with 94% probability. And it was not free of harm: lower-limb adverse events ran 100 in the walking group against 54 in the control group.\n\nFor pain that is already chronic rather than recurring, structured exercise pooled across 249 randomised trials in people produced roughly a 15-point improvement on a 0–100 scale against no treatment or usual care — about double what an anti-inflammatory delivers for acute pain, and roughly five times what one delivers for chronic pain.",
{
"type":"source",
"id":"s10"
},
"That is the whole evidence-based core of a disc recovery plan, and it is walking and loading. Everything else on this page is added on top of it, and nothing else on this page has a number that comes close.\n\n## Three things sold as the raw material for the rebuild were tested and did nothing\n\nThe intuition that a rebuilding tissue needs feeding is reasonable. The intuition has been tested three times and lost three times, and a page that skipped that would be selling something.\n\nCollagen. Thirty-nine recreationally active men took either 15 g of collagen peptides daily or a placebo through 15 weeks of supervised lower-body resistance training. Both groups gained tendon stiffness (+17.3% collagen, +20.9% placebo) and Young's modulus (+17.8% versus +20.6%). Between the groups, nothing: no difference on any tendon measure, with p-values between 0.365 and 0.877. The training built the tendon. The powder added nothing detectable.",
{
"type":"source",
"id":"s12"
},
"Vitamin D. Ten randomised trials in people with chronic low back pain, pooled: standardised mean difference −0.130 (95% CI −0.260 to 0.000), which touches zero. Long-term dosing did not help either, and neither did the active forms. Baseline vitamin D status made no difference to the result.",
{
"type":"source",
"id":"s13"
},
"Weight loss on its own, once exercise is already in place. Across 22 trials and 3,602 people, weight-loss interventions beat minimal care on pain (SMD −0.54) — but head to head against exercise alone, in four trials and 673 people, weight loss was no better (SMD −0.13, 95% CI −0.40 to 0.14). The credibility of the whole body of evidence was rated very low.",
{
"type":"source",
"id":"s11"
},
"That last result is a compounding finding, not a single-factor one, and it is the first of only three real interaction measurements on this entire page. Weight loss and exercise are not additive in the way the arithmetic of the two-speeds model would suggest. They overlap. Buying both does not buy you twice.\n\n## Each peptide is aimed at a different step, and none has been put near a disc\n\nBPC-157 is a fifteen-amino-acid chain based on a sequence found in human stomach fluid. In rats it raises VEGF, the signal that grows new blood vessels into damaged tissue, and drives connective-tissue cells to move into an injury and rebuild it. A cut rat Achilles tendon treated with it came back mechanically stronger than an untreated one.\n\n![[bpc-157]]\n\nTB-500 is a seven-amino-acid fragment of a larger natural protein, thymosin beta-4. In animals it acts on cell movement and on the organisation of collagen laid down in a healing wound. The molecule in the vial and the molecule in most of the published research are not the same thing, which is covered in full on its own page.\n\n![[tb-500]]\n\nThe reason a nerve compound is in a disc stack at all is that a large share of the pain is chemical rather than mechanical. Material leaking from a torn disc releases TNF-alpha and IL-1beta onto the nerve root, and those two signals are the ones tied to both the ongoing breakdown of the disc and the pain itself.",
{
"type":"source",
"id":"s5"
},
"ARA-290 is the only one of the three with randomised human evidence of any kind. In a 28-day phase 2b trial, 64 people with sarcoidosis-related small nerve fibre loss and nerve pain took 1, 4 or 8 mg a day or placebo. At 4 mg the corneal nerve fibre area rose by 697 µm² over placebo (95% CI 159–1,236, p=0.012), and regenerating skin nerve fibres rose too (p=0.035). Pain improved in every group including placebo; the placebo-corrected pain difference in the moderate-to-severe subgroup did not reach significance (p=0.157).",
{
"type":"source",
"id":"s16"
},
"![[ara-290]]\n\nRead that carefully, because it is the strongest human result any compound in this stack has, and it is about a nerve in an eye of a person with sarcoidosis. Nobody has run ARA-290 against a nerve root squeezed by a disc. Human evidence in one tissue and one disease does not transfer to another by argument.\n\nRetatrutide is not a disc compound at all. It is a weight-loss drug, and its only relevance here runs through the body-mass row of the table above: less load on the column, no direct action on disc tissue.\n\n![[retatrutide]]\n\n![[what-are-peptides-herniated-disc]]\n\n## The one experiment that tested the pair found no bonus for taking both\n\nThis is the single most important result on this page, and it is the one that the phrase \"the repair pair\" was invented before anybody had.\n\nIn 2026, 32 male Sprague-Dawley rats, each about 330 g, had their Achilles tendon cut and repaired, then were split into four groups of eight: control, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, and both together. Everything was injected into the belly, daily, for four weeks.\n\nResults, arm by arm:\n\n| Arm | Load to failure | Tissue architecture score | Verdict |\n|---|---|---|---|\n| Control | baseline | baseline | — |\n| BPC-157 alone | higher, not statistically significant | numerically better, not significant | signal without proof |\n| TB-500 alone | higher, significant (p<0.05) | Bonar p=0.016, Movin p=0.017 | the only arm that moved the mechanical number |\n| Both together | not significantly better than either alone | Movin p=0.040 | no bonus for the second compound |\n\nThe authors' own sentence: \"Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone.\"",
{
"type":"source",
"id":"s9"
},
"Their proposed explanation is that the two compounds converge on the same downstream machinery, so the second one has nothing left to add. They flag it as a hypothesis needing confirmation.\n\nNow negate it properly, because a single result does not settle a question in either direction. Eight rats per arm is small. An additive effect of, say, 15% would very likely be missed at that sample size. The endpoint was a tendon at four weeks, not a disc at six months. The route was into the belly, which is not how anybody takes either compound. And no dose-response work was done, so a different ratio of the two might behave differently. What the experiment establishes is narrow and real: at these doses, in this tissue, on these endpoints, the pair did not beat the better single compound. What it does not establish is that combining them is pointless everywhere.\n\nThe claim it does damage to is specific. Anyone who tells you the two compounds are synergistic is describing a mechanism, not a measurement. The measurement exists, it was taken in 2026, and it came back flat.\n\n## Six real combinations, side by side\n\nNobody chooses one row of the tables above. They choose a whole column of behaviour. Here are six combinations a person with a bad disc actually ends up in, with what is known about each part, what is known about the parts in combination, and where the interaction has never been measured.\n\n| The combination | What each part is measured at, alone | What is measured about the combination | Never measured |\n|---|---|---|---|\n| **A. Walking 25 min/day + adequate protein + BPC-157 + TB-500** | Walking: hazard ratio 0.72, 701 people, HUMAN. Protein/collagen: no tendon effect over placebo in 39 men, HUMAN. BPC-157: rat tendon repair, ANIMAL. TB-500: rat tendon repair, ANIMAL | The two peptides together: no benefit beyond either alone in 32 rats, ANIMAL | Walking with either peptide, in any species. Any of it in a human disc |\n| **B. Smoking + no movement + repeated steroid injections + daily anti-inflammatories** | Smoking: odds 1.22, HUMAN. Sitting: odds 1.78, HUMAN. Each steroid injection: 1.21× fracture risk, HUMAN. Anti-inflammatories: 7.29/100 points of pain relief and suppression of the clearance mechanism, HUMAN | Nothing. Not one study has combined these four | Everything. This is the most common real-world combination and the least studied |\n| **C. Walking alone, nothing else changed** | Hazard ratio 0.72 for recurrence; ~15/100 points for chronic pain across 249 trials, HUMAN | This is the measured baseline every other row should be compared against | — |\n| **D. Both peptides, no change to movement or weight** | Rat tendon data only, ANIMAL | The pair, in rats: no additive benefit, ANIMAL | Whether peptides do anything at all when the load driving the damage is unchanged |\n| **E. Weight loss on a GLP-1 drug + walking, no peptides** | Weight: odds 1.26 per unit of body mass index, HUMAN. Walking: hazard ratio 0.72, HUMAN | Weight loss versus exercise alone, head to head: no added benefit, 4 trials, 673 people, HUMAN | Retatrutide specifically — a 586-person trial is running and reports in 2027 |\n| **F. Everything: walking + weight loss + BPC-157 + TB-500 + ARA-290** | Each part as above; ARA-290 has 64-person HUMAN data in a different disease | Nothing whatsoever | The entire combination. No study in any species has given three of these compounds together |\n\nRead column three. Across six combinations, the total measured interaction evidence is three findings: weight loss adds nothing on top of exercise in people, the two peptides add nothing on top of each other in rats, and nothing else has been looked at.\n\n## The interactions nobody has measured, written down so the holes are visible\n\nNaming a gap is a finding. These are the specific pairs and triples that a person assembling a stack is implicitly betting on, with no measurement behind them:\n\n- BPC-157 combined with any form of exercise, in any species.\n- Either peptide combined with an anti-inflammatory drug — which matters, because the drug suppresses the same new-blood-vessel step the peptide is proposed to drive. Rats given BPC-157 alongside diclofenac had less gut damage, but nobody measured the tendon.\n- ARA-290 combined with either of the other two, in any species.\n- Any of the three during active shrinking of a herniation, where the body's own immune clean-up is already running.\n- Weight loss combined with either peptide.\n- All three peptides together, which is what the popular stack actually is.\n- Any of it against the 66.66% background rate of the disc fixing itself. This is the sharpest hole: without a control arm, a person who improves on a stack cannot tell whether the stack did it or whether they were in the two-thirds.\n\n## Every claim above, against the thing that would break it\n\nA claim counts as established only after it has survived its own negation. Here is each substantive claim on this page put against what would falsify it, and whether that test has been run.\n\n| Claim | Tier | What would break it | Has that been tested? |\n|---|---|---|---|\n| Most herniations shrink without treatment | HUMAN | A cohort where imaging shows no change in most people | Tested repeatedly; 11 cohorts pooled at 66.66% |\n| Walking lowers the recurrence rate | HUMAN | A randomised trial where the walking arm relapses as fast as controls | Tested; 701 people; walking arm went 96 days longer |\n| Sitting is the largest modifiable driver of degeneration | HUMAN | A causal-genetic study putting television time below smoking or weight | Tested in 20 pooled studies; television time came out highest at 1.78 |\n| Supplying raw material speeds tissue rebuilding | HUMAN | A trial where collagen plus training beats training alone | Tested; 39 men, 15 weeks, no between-group difference |\n| Vitamin D helps chronic back pain | HUMAN | A pooled result whose confidence interval excludes zero | Tested; 10 trials; interval touches zero |\n| Weight loss adds to exercise | HUMAN | A head-to-head trial where the combined arm beats exercise alone | Tested; 4 trials, 673 people; no added benefit |\n| BPC-157 and TB-500 are synergistic | ANIMAL | An experiment where the combined arm beats both single arms | Tested once, 2026, 32 rats: the combined arm did not beat either alone |\n| BPC-157 rebuilds tendon | ANIMAL | Rat tendons treated with it failing at the same load as controls | Tested; treated tendons failed at higher loads; never tested in a person |\n| ARA-290 regrows nerve fibres | HUMAN | A randomised trial where nerve fibre area does not rise over placebo | Tested; rose 697 µm² over placebo at 4 mg, p=0.012, in sarcoidosis |\n| ARA-290 relieves nerve pain from a squeezed nerve root | — | Any randomised trial in that population | Never run. This claim is untested, not supported |\n| Any peptide here changes a human disc | — | An imaging trial with a placebo arm | Never run in any species |\n| Repeated steroid injections are consequence-free | HUMAN | A matched cohort showing no rise in fracture risk with injection count | Tested; each injection multiplied fracture risk by 1.21 |\n| Sleep matters to how a disc feels | HUMAN | A crossover trial where cutting sleep does not change pain thresholds | Tested; 39 volunteers; cutting sleep by 40% raised pain sensitivity, with no change in inflammatory blood markers |",
{
"type":"source",
"id":"s15"
},
"One row deserves adding, because it is the only human evidence that a degenerated disc responds to anything regenerative at all. Pooled across trials of stem cell injection into painful degenerated discs, pain and disability scores improved — small studies, early, and the only positive human regeneration signal that exists for this tissue.",
{
"type":"source",
"id":"s6"
},
"The three rows with no tier are the honest edge of this subject. They are not weak evidence. They are absence of evidence, and they sit in a table rather than in the headline because eleven of the fourteen rows above them have real numbers.\n\n![[herniated-disc]]\n\n## Fifteen people who ran a combination, counted\n\n**Fifteen first-person accounts on X, all self-reported, none verified, none from any trial. Ten of them ran two or more compounds together for a spine problem, and five ran BPC-157 on its own. One further account reports harm from the pair at a different site.**\n\n**Of the ten who stacked, seven reported it helped, two reported partial benefit, and one reported none.**\n\nThree weeks on the pair after an L4-L5 herniation, back on a basketball court against two months last time:",
{
"type":"source",
"id":"s22"
},
"A 2017 L4/L5/S1 herniation with a degeneration diagnosis, and this person says he was pain-free within a month on the pair:",
{
"type":"source",
"id":"s23"
},
"ARA-290 plus BPC-157 plus TB-500 for one month after spine surgery, with the sciatica reported 95% gone:",
{
"type":"source",
"id":"s24"
},
"Lower spine degeneration, barely able to stand upright, and this person reports being pain-free on the pair and still dosing:",
{
"type":"source",
"id":"s25"
},
"Retatrutide alongside a BPC-157/TB-500 blend, low back reported much improved — the only account here combining a weight-loss drug with the peptides:",
{
"type":"source",
"id":"s27"
},
"Three compounds at once for severe back pain, reported cleared in three to four weeks:",
{
"type":"source",
"id":"s28"
},
"Severe leg pain, reported 75% better the same evening and gone by day three:",
{
"type":"source",
"id":"s30"
},
"**Partial — 2 of 10.** One month of the pair for lifelong back pain: recovery between flares got faster, and the pain is still there.",
{
"type":"source",
"id":"s26"
},
"Six weeks of the pair for a dried-out lowest disc: biceps and shoulder pain gone, the disc itself only partly better and still needing physiotherapy.",
{
"type":"source",
"id":"s29"
},
"**No benefit — 1 of 10.** One person ran the pair alongside a second stack for joint damage and called the whole thing a waste of money.",
{
"type":"source",
"id":"s31"
},
"**Of the five who ran a single compound, one reported it helped, three reported nothing, and one reported that one compound did nothing for him while a different one worked.**\n\nL5/S1 herniation, BPC-157 alone and deliberately unpaired, 90% pain reduction in two weeks:",
{
"type":"source",
"id":"s33"
},
"The same compound healing a wrist and doing nothing for the same person's disc:",
{
"type":"source",
"id":"s34"
},
"A week of it to avoid neck surgery; the surgery happened anyway:",
{
"type":"source",
"id":"s35"
},
"Oral capsules taken instead of injections, and no help for a back:",
{
"type":"source",
"id":"s37"
},
"One compound nothing for a back injury, the other clearing it in five days — which is the closest thing in this entire set to a within-person comparison, and it points at the two compounds not being interchangeable:",
{
"type":"source",
"id":"s36"
},
"**Harm — 1 report.** Two months of the pair for knees brought slight improvement in the joints, along with badly disrupted sleep and lowered heart-rate variability. Both the sleep and the heart-rate variability went back to normal after stopping.",
{
"type":"source",
"id":"s32"
},
"**What fifteen accounts settle, and what they cannot.** They cannot compare the stack against a single compound, even though the numbers above look like they do. The stacked group reported a better outcome rate than the single-compound group — 7 of 10 against 1 of 5 — and that difference is worthless as evidence. People who buy three vials have spent more, expect more, and are more likely to post a result. People who describe a null outcome tend to be answering somebody else's thread rather than writing their own. And every single one of these people is running against a background rate where two thirds of herniations resolve regardless.\n\nWhat the accounts do settle is narrower and still worth having. The reported experience is not uniformly positive: four of fifteen describe no benefit for a spine, and one describes a genuine harm. Timelines that people report cluster at two to six weeks, which is faster than any animal tendon study would predict and is exactly the window in which spontaneous shrinking also happens. Nobody in this set reported a serious adverse event.\n\n## Two registry entries that would move a row each, and a third that is only a template\n\nTwo entries on ClinicalTrials.gov are marked recruiting and would each convert one row of the tables above from mechanism into measurement. Neither of them is a disc. A third entry is listed below because it circulates as though it were a trial, and it is not one.\n\n| Registry ID | What it tests | Size | Primary endpoint | Reports |\n|---|---|---|---|---|\n| NCT07035093 | Retatrutide in people with obesity or overweight and chronic low back pain, phase 3, Eli Lilly | 586 | Pain intensity and body weight change, to 72 weeks | Estimated September 2027 |\n| NCT07437547 | BPC-157 for acute hamstring strain, phase 2, Hudson Biotech | 120 | Days to unrestricted sport, and MRI injury volume at day 14 under blinded central review | Estimated February 2027 |\n| NCT07487363 | Not a trial. A record that declares itself a fictional example, written in the style of a TB-500 study of cardiovascular markers in stable arterial disease, phase 1/2, Hudson Biotech | 80, stated inside the example | Treatment-emergent adverse events at 12 weeks, stated inside the example | Nothing will ever report |\n\nRead the third row against its own record before counting it. The public summary of NCT07487363 opens: \"This fictional study is an example of a ClinicalTrials.gov-style record.\" Its dose field says the levels \"are not provided in this public example.\" It is a demonstration template, and any page citing it as proof that TB-500 is being tested in people is citing a placeholder. Its sponsor, Hudson Biotech, filed eight entries of that shape between 2 and 15 February 2026, one of which is the BPC-157 hamstring entry in the row above it.",
{
"type":"source",
"id":"s18"
},
{
"type":"source",
"id":"s19"
},
{
"type":"source",
"id":"s20"
},
"The BPC-157 hamstring trial is the one worth watching, because MRI injury volume under blinded review is the first objective tissue measurement of this compound in a person. If it comes back flat, the entire rat literature stops transferring. If it comes back positive, the disc question becomes worth running rather than worth arguing about.\n\n## What holds always, what holds never, and what depends on something\n\n**Foundational — true with everything else stripped away.** The disc has almost no blood supply and rebuilds slowly. Immune cells and new blood vessels are what remove a herniated fragment. Load, weight, sitting time, smoking and blood sugar act on the breakdown speed. Movement acts on the rebuild speed. BPC-157 and TB-500 are proposed to act on the rebuild speed by improving blood vessel growth and connective tissue repair. ARA-290 acts on nerve fibres, not on the disc.\n\n**Always true.** Two out of three herniations shrink without treatment, so any uncontrolled personal result is uninterpretable. Every steroid injection adds fracture risk in proportion to the count. Any claim about a peptide in a human disc rests on zero measurements in any species.\n\n**Never true.** No compound named on this page is an approved medicine for a disc anywhere in the world. No published experiment has found a bonus from combining BPC-157 with TB-500 — the one experiment that tested it found none. No trial has combined a peptide with exercise, with weight loss, or with an anti-inflammatory.\n\n**Conditional, with the dependency named.** Walking lowers recurrence risk by 28% — in adults who have recently recovered from an episode, over six months of a progressive programme with physiotherapist contact, not in someone in acute pain today. Stopping smoking halts further degeneration and partly restores the gel in the soft centre — in rats, over eight weeks, and it does not reverse the structural misalignment. ARA-290 regrows nerve fibres — in 64 people with sarcoidosis, at 4 mg a day for 28 days, measured in the cornea. BPC-157 strengthens a healing tendon — in rats, injected into the belly, at 10 µg/kg/day, measured at four weeks. TB-500 improves tendon architecture and load to failure — in rats, at 60 µg/kg/day, on the same schedule. Weight loss reduces back pain — against minimal care, and not against exercise.\n\nRed-flag symptoms are the exception to everything above and are not a matter of weighing evidence: loss of bladder or bowel control, numbness across the area that would contact a saddle, or weakness that is getting worse are emergencies and need a hospital the same day. Nothing on this page is a dose, a schedule or a recommendation to take anything, and every compound named is unapproved for disc disease. TB-500 and BPC-157 are both banned in tested sport at all times."
],
"facts": {
"converted_from":"markdown",
"original_updated":"2026-08-04T20:25:42.660Z",
"register":"essay",
"category":null
},
"hero":"https://miscsubjects.com/img/up/the-disc-stack-hero-card.png",
"model":"Fable 5 (Claude Code)",
"tags": [
"stack",
"disc",
"herniated-disc",
"degenerative-disc-disease",
"peptides"
],
"sources": [
{
"id":"s1",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9820240/",
"title":"Discogenic Low Back Pain: Anatomy, Pathophysiology and Treatments of Intervertebral Disc Degeneration",
"quote":"The IVD is one of the avascular tissues which only received small arteries supplying the outermost peripheral fibers of the AF.",
"claim_ids": [
"c1"
],
"accessed_at":"2026-08-04T19:42:59.970Z",
"prev":"genesis",
"hash":"996feafed9d5d49b3b00d641338f868493499e0214cb6f3b04636e3556467fa5",
"plain":"Sets out the hard problem behind everything else here: almost no blood reaches the disc, so the delivery route that carries repair signals everywhere else in the body barely exists. Background anatomy rather than a test of anything.",
"quote_sha256":"8cb4b5ce067efc4ea3569bc30a44adfe014363d86321f2444b3f8b8c786a55e0"
},
{
"id":"s2",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/28072796/",
"title":"Incidence of Spontaneous Resorption of Lumbar Disc Herniation: A Meta-Analysis",
"quote":"The overall incidence of spontaneous resorption after LDH was 66.66% (95% CI 51% - 69%).",
"claim_ids": [
"c2"
],
"accessed_at":"2026-08-04T19:42:59.970Z",
"prev":"996feafed9d5d49b3b00d641338f868493499e0214cb6f3b04636e3556467fa5",
"hash":"f0070309778a1f84e012891f03a0069fabfcfe2b95a3cd2440289bf81da7f6f8",
"plain":"Pools imaging follow-up studies to ask how often a herniation shrinks on its own, and roughly two in three do. The pooled studies watched different people for different lengths of time and shrinking on a scan is not the same as feeling better, but this is the baseline anything else has to beat.",
"quote_sha256":"72ff46b44c376e1fe4c960a005c7d902dc8a41df790b21aff3be19ddcd4fe42b"
},
{
"id":"s3",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9396855/",
"title":"Characteristics and mechanisms of resorption in lumbar disc herniation",
"quote":"Macrophage infiltration and activation are critical steps in the process of reabsorption.",
"claim_ids": [
"c2"
],
"accessed_at":"2026-08-04T19:42:59.970Z",
"prev":"f0070309778a1f84e012891f03a0069fabfcfe2b95a3cd2440289bf81da7f6f8",
"hash":"e60309eee0580676d90682f5c59f3fca8fd6b09f3e5d91b1dd27e24ae82f6c39",
"plain":"Names the machinery behind that shrinking — immune cells moving in to clear the extruded material away — which makes the target concrete, since anything that helps has to help those cells reach the site. Mechanism work, not a test of any treatment.",
"quote_sha256":"a8eb22f9d44b979da618527145a4a0e3eea2d5f195a7641a30c0cd26b4b1c434"
},
{
"id":"s4",
"type":"pubmed",
"url":"https://academic.oup.com/aje/article/179/8/929/108237",
"title":"Obesity as a Risk Factor for Sciatica: A Meta-Analysis",
"quote":"Both overweight (OR = 1.23) and obesity (OR = 1.40) were associated with lumbar radicular pain.",
"claim_ids": [
"c3"
],
"accessed_at":"2026-08-04T19:42:59.970Z",
"prev":"e60309eee0580676d90682f5c59f3fca8fd6b09f3e5d91b1dd27e24ae82f6c39",
"hash":"6ff65ee95ba89c5f9df8cb26b8086878a2e5ed0b0e5d762e09ede5e47477c674",
"plain":"Population studies pooled to link body weight with nerve pain down the leg, where the rise is real but modest and the link is association, since heavier people differ in other ways too. It earns its place because weight is one of the few items here a person moves directly.",
"quote_sha256":"d706420617684fdd500359f434671bf241142941cceb60880a75dca48cf5ad0b"
},
{
"id":"s5",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4751407/",
"title":"Disc in Flames: Roles of TNF-alpha and IL-1beta in Intervertebral Disc Degeneration",
"quote":"Inflammatory processes, exacerbated by cytokines TNF-alpha and IL-1beta are believed to be key mediators of disc degeneration and low back pain.",
"claim_ids": [
"c4"
],
"accessed_at":"2026-08-04T19:42:59.970Z",
"prev":"6ff65ee95ba89c5f9df8cb26b8086878a2e5ed0b0e5d762e09ede5e47477c674",
"hash":"3685068619d028e38ffd474648ca22019c8872975512a4f69b2a3affd8d020e3",
"plain":"A review naming the two inflammatory signals that turn up in both the wearing-down of the disc and the nerve pain of a herniation — one target, two problems. The source hedges its own wording, and a review builds a case rather than testing one.",
"quote_sha256":"c5337f8e0926176bf7fd1e6f470c5b0d6afa4e13fc6bb198534db4ee4f374fe5"
},
{
"id":"s6",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10313064/",
"title":"Mesenchymal stem cells can improve discogenic pain in patients with IVD degeneration: a meta-analysis",
"quote":"MSCs injection therapy may be effective in relieving discogenic low back pain and improving Oswestry Disability Index significantly",
"claim_ids": [
"c5"
],
"accessed_at":"2026-08-04T19:42:59.970Z",
"prev":"3685068619d028e38ffd474648ca22019c8872975512a4f69b2a3affd8d020e3",
"hash":"488449714a3913850bf6311ee0a9fd0546d567d6ed792416bd5f788a74ed20c6",
"plain":"Human injection trials pooled, with real pain and disability scores that moved, making this the strongest evidence here that a disc can be pushed toward repair at all. The pooled trials are few and small, and an injection placed into the disc is nothing anyone does at home.",
"quote_sha256":"4f3c210866ac4586dc44c6b432d3af516cc946b453558226af6c09aba2a93c5f"
},
{
"id":"s7",
"url":"https://pubmed.ncbi.nlm.nih.gov/38908392/",
"title":"WalkBack: individualised progressive walking to prevent low back pain recurrence — randomised trial, 701 adults (Lancet 2024, PMID 38908392)",
"quote":"The intervention was effective in preventing an episode of activity-limiting low back pain (hazard ratio 0.72 [95% CI 0.60-0.85], p=0.0002). The median days to a recurrence was 208 days (95% CI 149-295) in the intervention group and 112 days (89-140) in the control group.",
"_id":"w_0yn4p2wd",
"_ts":"2026-08-04T19:36:46.263Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:46.263Z",
"claim_ids": [],
"prev":"488449714a3913850bf6311ee0a9fd0546d567d6ed792416bd5f788a74ed20c6",
"hash":"08269f07512db558032dfccd9e5a6c91ea288b26ae01f7a37db4fe633e811a8c",
"plain":"701 adults, randomly assigned and followed until back pain returned, with walking pushing the next episode from under four months out to nearly seven. Ordinary walking built up gradually, tested at a scale most recovery advice never reaches, and aimed at the next flare rather than the disc.",
"quote_sha256":"1797c6030bd4797cb75fd47df5fd4218a0a88a3d383655c0e637dafc12c953e0"
},
{
"id":"s8",
"url":"https://pubmed.ncbi.nlm.nih.gov/42243749/",
"title":"Causal links between multi-domain risk factors and disc degeneration: meta-analysis of 20 Mendelian randomization studies (BMC Musculoskelet Disord 2026, PMID 42243749)",
"quote":"Key lifestyle and metabolic risk factors were time watching TV (OR = 1.78, 1.52-2.08), smoking initiation (OR = 1.22, 1.12-1.33), greater height (OR = 1.14, 1.09-1.20), larger waist circumference (OR = 1.26, 1.04-1.53), body mass index (OR = 1.26, 1.14-1.38), triglycerides (OR = 1.08, 1.03-1.13), and Type 2 diabetes (OR = 1.05, 1.03-1.07).",
"_id":"w_cj857win",
"_ts":"2026-08-04T19:36:46.497Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:46.497Z",
"claim_ids": [],
"prev":"08269f07512db558032dfccd9e5a6c91ea288b26ae01f7a37db4fe633e811a8c",
"hash":"9437bcf26f9ff34c88f8d1d6c578130d1e226927869b213cf3d18d0325be8b74",
"plain":"Uses inherited genetic differences as a natural experiment, closer to cause than ordinary population data, with sitting time, smoking, waist size, body mass, blood fats and diabetes all pointing the same direction. Each effect is small, and it cannot say that changing them now undoes damage.",
"quote_sha256":"5ce1f466e3d7ea00ea87d5f3aaa290ea0af3e4aabfcb154a5d0f5d28482a539b"
},
{
"id":"s9",
"url":"https://pubmed.ncbi.nlm.nih.gov/42542926/",
"title":"BPC-157, TB-500 and the two together on rat Achilles healing — 32 rats, 8 per arm (Jt Dis Relat Surg 2026, PMID 42542926)",
"quote":"Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone. ... The absence of additive effects with combination therapy may reflect convergence on shared downstream pathways; however, this hypothesis requires further experimental confirmation.",
"_id":"w_gnhmfjsd",
"_ts":"2026-08-04T19:36:46.868Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:46.868Z",
"claim_ids": [],
"prev":"9437bcf26f9ff34c88f8d1d6c578130d1e226927869b213cf3d18d0325be8b74",
"hash":"6b1a89f7b5e94a6f2b9477c1f0dd192831e94e0797dda38d96ac6bda305a62be",
"plain":"32 rats, eight per group, cut Achilles tendon, and the two compounds together did no better than either alone — the only direct test of the pairing anywhere here, and it came back flat. A rat tendon is not a human disc, but nothing closer exists.",
"quote_sha256":"01bbcc2ef892d871060c7719b3eaca2277438219c150da5b9293d866a577e87c"
},
{
"id":"s10",
"url":"https://pubmed.ncbi.nlm.nih.gov/34580864/",
"title":"Exercise therapy for chronic low back pain (Cochrane 2021, 249 trials, PMID 34580864)",
"quote":"Exercise treatment ... is probably more effective than no treatment, usual care or placebo for pain and functional limitations in adults with chronic low back pain.",
"_id":"w_yzq0j56j",
"_ts":"2026-08-04T19:36:47.127Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:47.127Z",
"claim_ids": [],
"prev":"6b1a89f7b5e94a6f2b9477c1f0dd192831e94e0797dda38d96ac6bda305a62be",
"hash":"89f2fa7996eff0960d5d17dcd58de7065eb5b62a18a74e9c49fa86c5a9db5d5e",
"plain":"249 trials pooled by reviewers who grade their own confidence rather than counting wins, with exercise coming out ahead of nothing, of usual care, and of placebo. It does not say which exercise, and the hedging in the wording is the reviewers' own confidence rating.",
"quote_sha256":"142863dea8838128048de96d309f9e27dc0a492704069023b20311cd1cf2d7d1"
},
{
"id":"s11",
"url":"https://pubmed.ncbi.nlm.nih.gov/32272032/",
"title":"Weight-loss interventions for pain and disability in musculoskeletal disorders — 22 trials, 3,602 participants (JOSPT 2020, PMID 32272032)",
"quote":"For knee OA, there was low- to moderate-credibility evidence that weight-loss interventions were not more effective than exercise only for pain intensity and disability (4 trials, n = 673; SMD, -0.13; 95% CI: -0.40, 0.14).",
"_id":"w_gfzrrptv",
"_ts":"2026-08-04T19:36:47.383Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:47.383Z",
"claim_ids": [],
"prev":"89f2fa7996eff0960d5d17dcd58de7065eb5b62a18a74e9c49fa86c5a9db5d5e",
"hash":"94e4998af6444260e0b7e02292c16b19b92d64f68f45bae8094f26fe353250fb",
"plain":"22 trials and more than 3,600 people, the honest counterweight to the weight argument: in knee arthritis, losing weight did no better than exercising alone. The knee is not the spine and the evidence is graded low to moderate, but it cuts against selling weight loss as the whole lever.",
"quote_sha256":"27a7866d89d201db12d334289b20c7e89e0bbe5eb020c1495dfe84d301760772"
},
{
"id":"s12",
"url":"https://pubmed.ncbi.nlm.nih.gov/37436929/",
"title":"15 g/day collagen peptides plus 15 weeks of resistance training, 39 men — tendon outcomes (Med Sci Sports Exerc 2023, PMID 37436929)",
"quote":"No between-group differences were detected for any of the tendinous tissue adaptations to RT (ANOVA group-time, 0.365 <= P <= 0.877).",
"_id":"w_2nlrhxrp",
"_ts":"2026-08-04T19:36:47.628Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:47.628Z",
"claim_ids": [],
"prev":"94e4998af6444260e0b7e02292c16b19b92d64f68f45bae8094f26fe353250fb",
"hash":"093a531144225f3431cf1aef1e33b64530810d78d446db3cbd8fdc3a8594506a",
"plain":"39 men, 15 weeks of lifting, a large daily collagen dose in one group, and tendon measurements that moved the same amount in both. A controlled human comparison that came back negative — the useful kind, and the reason collagen sits low here.",
"quote_sha256":"d6cf00aaf2e7873d7da9064665f6ad700fcd0cbd4ac4022791fae18675bbfd86"
},
{
"id":"s13",
"url":"https://pubmed.ncbi.nlm.nih.gov/39477425/",
"title":"Vitamin D supplementation for chronic low back pain — 10 randomised trials (In Vivo 2024, PMID 39477425)",
"quote":"The results indicated that vitamin D supplementation did not significantly reduce pain scores compared to control groups (SMD: -0.130, 95%CI=-0.260 to 0.000; I2=0%), regardless of participants' baseline vitamin D levels.",
"_id":"w_so9yenfc",
"_ts":"2026-08-04T19:36:47.836Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:47.836Z",
"claim_ids": [],
"prev":"093a531144225f3431cf1aef1e33b64530810d78d446db3cbd8fdc3a8594506a",
"hash":"19146135d9fe02b98e3c457eb02bf387803c61eae3b2faad9ecbf9a0456ee531",
"plain":"Ten randomised trials pooled, with pain scores that did not shift even in people who started out low on vitamin D, which removes the usual objection that the wrong people were tested. Chronic low back pain only.",
"quote_sha256":"7f73464e4f09cc27d6c8b104d77b6214c72474b5045ece1e44c5dcdf89741612"
},
{
"id":"s14",
"url":"https://pubmed.ncbi.nlm.nih.gov/23780532/",
"title":"Vertebral body fractures after lumbar epidural steroid injections — 3,000 injected vs 3,000 propensity-matched controls (JBJS Am 2013, PMID 23780532)",
"quote":"Each successive injection increased the risk of fracture by a factor of 1.21 (95% confidence interval, 1.08 to 1.30).",
"_id":"w_21tppet5",
"_ts":"2026-08-04T19:36:48.064Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:48.064Z",
"claim_ids": [],
"prev":"19146135d9fe02b98e3c457eb02bf387803c61eae3b2faad9ecbf9a0456ee531",
"hash":"2a29a3b8a9a1d5a0927843317ab01ed5bbbf1357aa376c9ab5c8c768b7e04d01",
"plain":"3,000 people who received spinal steroid injections matched against 3,000 who did not, with each further injection raising the odds of a spinal fracture by about a fifth. Matched records rather than a randomised trial, so other differences can hide inside, but this is the cost side of a common procedure.",
"quote_sha256":"f356a2b51ce53ca4bc0353e76e0cbad12ffa3985b430a928a9a1d258cf72b05e"
},
{
"id":"s15",
"url":"https://pubmed.ncbi.nlm.nih.gov/41021423/",
"title":"Partial-night sleep restriction and pain sensitivity — 39 healthy volunteers, crossover (Scand J Pain 2025, PMID 41021423)",
"quote":"Experimental partial-night sleep restriction increases pain sensitivity, but does not alter inflammatory plasma biomarkers.",
"_id":"w_9ascap56",
"_ts":"2026-08-04T19:36:48.312Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:48.312Z",
"claim_ids": [],
"prev":"2a29a3b8a9a1d5a0927843317ab01ed5bbbf1357aa376c9ab5c8c768b7e04d01",
"hash":"2148c19b2e277e2733b3a107677dfe8734fa7afd4a13d9558037e133ee2b7639",
"plain":"39 healthy volunteers, each acting as their own comparison, with short sleep imposed deliberately: sensitivity to pain rose while blood markers of inflammation stayed flat, pointing at the nervous system rather than swelling. Healthy people over a few nights, not people with a damaged disc.",
"quote_sha256":"2336e544a510e8bfa5bebfc16735c9080f2380877579b1c047ff40ac3da80e34"
},
{
"id":"s16",
"url":"https://pubmed.ncbi.nlm.nih.gov/28475703/",
"title":"Cibinetide (ARA-290) phase 2b in sarcoidosis-associated small nerve fibre loss — 64 people, 28 days (IOVS 2017, PMID 28475703)",
"quote":"The placebo-corrected mean change from baseline CNFA at day 28 was 109 (95% CI, -429, 647), 697 (159, 1236; P = 0.012), and 431 (-130, 992) in the 1, 4, and 8 mg groups, respectively.",
"_id":"w_56fgfuwv",
"_ts":"2026-08-04T19:36:48.561Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:48.561Z",
"claim_ids": [],
"prev":"2148c19b2e277e2733b3a107677dfe8734fa7afd4a13d9558037e133ee2b7639",
"hash":"101a955fc55ee997e0bfc89c8555fdbfad407d00df136fa9592d54cc7033d123",
"plain":"64 people, 28 days, placebo-controlled, in nerve fibre loss caused by sarcoidosis, where only the middle dose clearly beat placebo and the highest did not — the opposite of a clean dose-response. Small, short, and a different condition from a pinched nerve root.",
"quote_sha256":"8b158061226cfe06f7b266513038568254d34d9ce0e76cc7cfeb1c9ac06892da"
},
{
"id":"s17",
"url":"https://pubmed.ncbi.nlm.nih.gov/16568393/",
"title":"Rat discs after 8 weeks of smoke exposure and after stopping (J Orthop Sci 2006, PMID 16568393)",
"quote":"After cessation, progression of degeneration ceased ... However, there were no changes in annulus fibrosus misalignment. Interleukin-1beta levels also remained significantly elevated after 8 weeks of cessation.",
"_id":"w_ptggy055",
"_ts":"2026-08-04T19:36:48.841Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:48.841Z",
"claim_ids": [],
"prev":"101a955fc55ee997e0bfc89c8555fdbfad407d00df136fa9592d54cc7033d123",
"hash":"7041f62426aa6034aef29ea9728fa8141443c581f45dbbc28b4fac4c9bf6c693",
"plain":"Rats exposed to smoke for eight weeks and then followed after it stopped: the decline halted, but the structural damage and one inflammatory signal both stayed put. Quitting stops the clock rather than turning it back, in rats, over a short window.",
"quote_sha256":"d66e0dabe810f01fb567dd4bf02345bded15cb4abdb7d8d127e122cdb72ff3ff"
},
{
"id":"s18",
"url":"https://clinicaltrials.gov/study/NCT07035093",
"title":"NCT07035093 — retatrutide in people with obesity or overweight and chronic low back pain, phase 3, 586 participants (Eli Lilly)",
"quote":"Primary outcomes: Change from Baseline in Pain Intensity Per Numeric Rating Scale; Percent Change from Baseline in Body Weight. Baseline, up to 72 weeks. Status: active, not recruiting. Start 2025-05-29. Estimated primary completion 2027-09.",
"_id":"w_0yi4abnb",
"_ts":"2026-08-04T19:36:49.072Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:49.072Z",
"claim_ids": [],
"prev":"7041f62426aa6034aef29ea9728fa8141443c581f45dbbc28b4fac4c9bf6c693",
"hash":"dc70f6bda99fd41c176f50207ee31f57de7cc44662be45c22ad0ff33beb097b5",
"plain":"A late-stage trial of a weight-loss drug measuring back pain intensity alongside weight in 586 people and running to 2027, which will be the first serious test of whether losing weight this way moves back pain. It has not reported, and the drug's maker runs it.",
"quote_sha256":"4a165b1139bd53d598806638f944989496a96dcecbc7b1acfda6f88c4baac9fb"
},
{
"id":"s19",
"url":"https://clinicaltrials.gov/study/NCT07437547",
"title":"NCT07437547 — BPC-157 for acute hamstring muscle strain, phase 2, 120 participants (Hudson Biotech)",
"quote":"Primary outcomes: Time to return to unrestricted sport participation (days), 8 weeks; Change from baseline to Day 14 in MRI-assessed hamstring injury volume (cm^3), blinded central radiology review. Status: recruiting. Actual start 2026-02-02. Estimated primary completion 2027-02-14.",
"_id":"w_vz2ju9d0",
"_ts":"2026-08-04T19:36:49.356Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:49.356Z",
"claim_ids": [],
"prev":"dc70f6bda99fd41c176f50207ee31f57de7cc44662be45c22ad0ff33beb097b5",
"hash":"ccfe6e249395fdfc7ad3d3fd5259e06d3b709ba3bb3d2b8d19355ef7b5f92764",
"plain":"The first registered human trial of this peptide on a real injury, using MRI-measured injury size rather than how people say they feel, in 120 people with results due 2027. It changes what will be knowable and establishes nothing right now.",
"quote_sha256":"76681335c9143d545c020297e8af52e482739ee017994d91056222bed7d76d1d"
},
{
"id":"s20",
"url":"https://clinicaltrials.gov/study/NCT07487363",
"title":"NCT07487363 — a record that declares itself a fictional example, written in the style of a TB-500 (thymosin beta-4 17-23 fragment) study of cardiovascular biomarkers in stable atherosclerotic disease, phase 1/2, 80 participants (Hudson Biotech)",
"quote":"Primary outcomes: incidence of treatment-emergent adverse events, 12 weeks; incidence of serious adverse events, 28 days. Status: recruiting. Actual start 2026-02-05. Estimated primary completion 2027-02-14.",
"_id":"w_1eobqphi",
"_ts":"2026-08-04T19:36:49.626Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:49.626Z",
"claim_ids": [],
"prev":"ccfe6e249395fdfc7ad3d3fd5259e06d3b709ba3bb3d2b8d19355ef7b5f92764",
"hash":"632d5a5aebb71cc2cf574c6a8dcb6874288e31202326c85b457b4106f7243db9",
"plain":"This is not a running trial. The record's own summary opens by saying it is a fictional example of a ClinicalTrials.gov-style entry, and its dose field says the levels are not provided in this public example. Nobody is being given TB-500 under it and it will never report a result. It is here because it circulates as if it were the human safety study this compound does not have.",
"quote_sha256":"ef27c166381ec81ddf0a89d7c153293a34c7a21c18887f02e31345d95a0589f4"
},
{
"id":"s21",
"url":"https://pubmed.ncbi.nlm.nih.gov/32297973/",
"title":"Anti-inflammatory drugs for acute low back pain — 32 trials, 5,356 participants (Cochrane 2020, PMID 32297973)",
"quote":"NSAIDs reduced pain ... mean difference -7.29, 95% CI -10.98 to -3.61 on a 0 to 100 scale ... the magnitude of these effects is small and probably not clinically relevant.",
"_id":"w_x6w1120w",
"_ts":"2026-08-04T19:36:49.879Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:49.879Z",
"claim_ids": [],
"prev":"632d5a5aebb71cc2cf574c6a8dcb6874288e31202326c85b457b4106f7243db9",
"hash":"ba6674b477c4c388fec19431863962054e3a26ff0ab7854862f57a402b6a1da8",
"plain":"32 trials and more than 5,000 people, with these drugs beating placebo by about seven points on a hundred-point pain scale — a gap the reviewers themselves call too small to matter to a person. It sets the bar every other option here is measured against.",
"quote_sha256":"81341f0f8350b820764e994a55f23842dec3550aefbe6672c73eaae609796fb2"
},
{
"id":"s22",
"url":"https://x.com/thebillyboone/status/2082100039707427193",
"title":"Herniated L4-L5, three weeks on BPC-157 with TB-500, back on the court (anecdotal, X, 2026-07-28)",
"quote":"Herniated L4-L5 disc 3 weeks ago hopped on the Wolverine stack (BPC-157/TB-500) This is today Took me 2 months to get back on the court last time",
"_id":"w_fztu0m4j",
"_ts":"2026-08-04T19:36:50.114Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:50.114Z",
"claim_ids": [],
"prev":"ba6674b477c4c388fec19431863962054e3a26ff0ab7854862f57a402b6a1da8",
"hash":"8ed824c44d895705f84ec6f670f09cf53ea4cc2eb469f093e8ac54ba311083f8",
"plain":"One person, a fresh disc herniation, three weeks on the pair, back on the court, measured against their own two-month recovery the previous time. A personal before-and-after is the weakest comparison there is, and nothing here was scanned or checked.",
"quote_sha256":"b6c0f48c88a6fbdbe3a14734216a0b20d54e4744269b21489ab4d792d58423fe"
},
{
"id":"s23",
"url":"https://x.com/jasonsvoboda/status/2081426443024961838",
"title":"Severe L4/L5/S1 herniation and a degeneration diagnosis, pain-free within a month on the pair (anecdotal, X, 2026-07-26)",
"quote":"BPC-157 / TB-500 Blew up my back in 2017. L4/L5/S1 severe disc herniation. Doc diagnosed me with degenerative disc disease... Found the Wolverine stack and within a month I was pain free.",
"_id":"w_8bybhpgx",
"_ts":"2026-08-04T19:36:50.387Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:50.387Z",
"claim_ids": [],
"prev":"8ed824c44d895705f84ec6f670f09cf53ea4cc2eb469f093e8ac54ba311083f8",
"hash":"d2f43df5247d8a5c48caa98e41f531e62622f65b8c4fb3b211bb2a507e22896f",
"plain":"An injury from 2017 with a degeneration diagnosis, recalled years afterward as resolving inside a month. Memory across that gap is unreliable, no imaging is offered, and most herniations improve on their own over that kind of window anyway.",
"quote_sha256":"44901b0136ae14f850cc232ff6e452c3d5f59d9407e4a19f7db28ba3a0652ad4"
},
{
"id":"s24",
"url":"https://x.com/cryptorayray89/status/2081141222719045707",
"title":"ARA-290 plus BPC-157 plus TB-500 for one month after back surgery, sciatica reported 95% gone (anecdotal, X, 2026-07-25)",
"quote":"I've been taking Ara290 and BPC 157 and Tb500 (Wolverine Stack) for 1 month so far and my sciatica is 95% gone. I've had major back surgery and have never had relief as well as I do now.",
"_id":"w_kasw14um",
"_ts":"2026-08-04T19:36:50.583Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:50.583Z",
"claim_ids": [],
"prev":"d2f43df5247d8a5c48caa98e41f531e62622f65b8c4fb3b211bb2a507e22896f",
"hash":"94ac3d5c98a45496ea87924444871e0d9c378e94cb09235016afeceda0a2c41c",
"plain":"Three compounds at once, a month after major back surgery, so nothing can be pinned on any one of them and recovery from the surgery is running in the background regardless. Reported as near-total relief from sciatica, better than anything that person had before.",
"quote_sha256":"5906244ead39f6cd87e18aec304e36c634dd45cfd643ddd20509c6b2fcf254c6"
},
{
"id":"s25",
"url":"https://x.com/KateinMB/status/2080854619593363787",
"title":"Lower spine degeneration, reported pain-free on BPC-157 with TB-500, still dosing (anecdotal, X, 2026-07-25)",
"quote":"I have disc degeneration in lower spine. Could barely get upright. BPC157 and TB500 made me pain free. (On maint/dose)",
"_id":"w_vyugmtzv",
"_ts":"2026-08-04T19:36:51.009Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:51.009Z",
"claim_ids": [],
"prev":"94ac3d5c98a45496ea87924444871e0d9c378e94cb09235016afeceda0a2c41c",
"hash":"00f7b40cdc3b4b57d79dc91b9ebc234d16bd0defbcd0525f777f3553f1db0750",
"plain":"Degeneration rather than a fresh herniation, and this person is still dosing, so it is a report from inside the course rather than a durable result afterward. No imaging and no comparison, but a plain functional shift described: barely able to stand up, then pain-free.",
"quote_sha256":"59d6177ad8af61d4fcc440a4c34bc6e9b7d5cde8c28a4668c69166cb17b7fc35"
},
{
"id":"s26",
"url":"https://x.com/BrandBarons/status/2080279766796562881",
"title":"One month of the pair for lifelong back pain — recovery faster, pain still present (anecdotal, X, 2026-07-23)",
"quote":"One month into the Wolverine stack (BPC-157 + TB-500). Lifelong chronic back pain. Lift 3x a week. Tweaked it yesterday... woke up this morning and it already felt better. Pain still there, but the recovery is noticeable.",
"_id":"w_yy4iraul",
"_ts":"2026-08-04T19:36:51.274Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:51.274Z",
"claim_ids": [],
"prev":"00f7b40cdc3b4b57d79dc91b9ebc234d16bd0defbcd0525f777f3553f1db0750",
"hash":"972068d12d518e9cd2fd88b60132bb8ae07a462a55adf6173575980cd5ac1afb",
"plain":"One month in, lifting three times a week, and the report is deliberately partial — faster bounce-back after a tweak, background pain unchanged. Accounts that stop short of a cure tend to be the more credible ones, and this one names exactly what did not move.",
"quote_sha256":"66adaf0fe30087c36a52487ab50f1b8699a7479e7bed5d12bdd8423da13c930a"
},
{
"id":"s27",
"url":"https://x.com/yakyusenshu23/status/2074846700674674986",
"title":"Retatrutide alongside a BPC-157/TB-500 blend, low back reported improved (anecdotal, X, 2026-07-08)",
"quote":"Reta has basically taken alcohol out of my life by 90%+... I do feel like bpc-157/tb500 blend has improved my joint and low back health immensely",
"_id":"w_ob3d3058",
"_ts":"2026-08-04T19:36:51.503Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:51.503Z",
"claim_ids": [],
"prev":"972068d12d518e9cd2fd88b60132bb8ae07a462a55adf6173575980cd5ac1afb",
"hash":"9c81149649a52e80b1af1d626e2898757af4e9b5c0d3df583a8fe95ec4a49a87",
"plain":"Two very different things at once, a weight-loss drug and the peptide blend, with joints and lower back described as much improved. Nothing separates losing weight from the peptides here, which is precisely the confusion the weight evidence elsewhere on this page raises.",
"quote_sha256":"1fdecf47134d38cc342b7e92c0d7e96287d625debfc950594bd5ad0f9d0fedfd"
},
{
"id":"s28",
"url":"https://x.com/mannyjplays/status/2062148959976526143",
"title":"Three compounds at once for back pain, cleared in three to four weeks (anecdotal, X, 2026-06-03)",
"quote":"I took BPC157, TB500 and ghk-cu for some pretty gnarly back pain and it cleared it within a 3-4 weeks... Ara 290 is specifically for nerve regeneration.",
"_id":"w_tl7gb049",
"_ts":"2026-08-04T19:36:51.755Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:51.755Z",
"claim_ids": [],
"prev":"9c81149649a52e80b1af1d626e2898757af4e9b5c0d3df583a8fe95ec4a49a87",
"hash":"b42b37ab6c9d9898a25a41d307ee7be3b67041f5a4cb5934358d6e0a441f4d01",
"plain":"Three compounds together for severe back pain, gone in three to four weeks by this account, with the usual stack problem: no way to tell which one, if any, did the work. The aside about nerve regeneration is that person's belief, not a finding.",
"quote_sha256":"a87808a45e705ce67ee8796adb2a953adc865dd903f17d49194600763d1e1862"
},
{
"id":"s29",
"url":"https://x.com/MuroCrypto/status/2083184469956059529",
"title":"Six weeks of the pair — shoulder and biceps resolved, the disc only partly (anecdotal, X, 2026-07-31)",
"quote":"My lowest disc in the lower back is dried out, almost no fluid left, classic herniated disc... In June I ran BPC-157 and TB-500 for about 6 weeks... After 3-4 weeks it already felt better. Now after the cycle, zero pain in biceps and shoulder. Disc still needs physio and rest, but already much better.",
"_id":"w_psefi25z",
"_ts":"2026-08-04T19:36:51.997Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:51.997Z",
"claim_ids": [],
"prev":"b42b37ab6c9d9898a25a41d307ee7be3b67041f5a4cb5934358d6e0a441f4d01",
"hash":"a7921e41b9e6967b8bef4fb6a69504f324df60aa3ae8290e55411634bfe6dfce",
"plain":"The most useful shape of report here — one person, one six-week course, different tissues — with shoulder and biceps pain clearing entirely while the dried-out disc improved only partly and still needed rest and physio. That split is what a tissue-specific effect would look like.",
"quote_sha256":"68bc385c6d2084875d5d9de31049debebd0e9fdf5e3a5462db5eec8f339dcfc7"
},
{
"id":"s30",
"url":"https://x.com/L0V3lsKeY/status/2083868515438666186",
"title":"Severe leg pain, reported gone over three days on BPC-157 with TB-500 (anecdotal, X, 2026-08-02)",
"quote":"Testimony regarding BPC-157/TB500 Peptides. Wednesday I woke up in severe pain in my L Leg... Peptides started in the afternoon. Leg 75% better in the evening... Friday: Woke up 90% better... Saturday: Woke up 100% better.",
"_id":"w_muht8t1q",
"_ts":"2026-08-04T19:36:52.228Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:52.228Z",
"claim_ids": [],
"prev":"a7921e41b9e6967b8bef4fb6a69504f324df60aa3ae8290e55411634bfe6dfce",
"hash":"c243e7ada8a847e8e4e7176c7e212ec2189dc366a706ad86bbd492e5ec220d5c",
"plain":"Severe leg pain reported as going from unbearable to gone across about three days, though nerve pain flares and settles by itself on roughly that timescale, which makes it the hardest sort of report to credit. It is here because this page does not keep only the convenient ones.",
"quote_sha256":"d0df5e85d76356a5651e7a51dff5abd25a7af7b8b6042377203f6990030b2fa3"
},
{
"id":"s31",
"url":"https://x.com/jakew/status/2057454035855094005",
"title":"The pair called a waste of money for joint damage (anecdotal, X, 2026-05-21)",
"quote":"My experience with BPC-157 and what I've observed in others is that Wolverine and GLOW are a waste of money if you're dealing with damage to a joint.",
"_id":"w_ysx2tq4l",
"_ts":"2026-08-04T19:36:52.490Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:52.490Z",
"claim_ids": [],
"prev":"c243e7ada8a847e8e4e7176c7e212ec2189dc366a706ad86bbd492e5ec220d5c",
"hash":"50b34edf3842fc49a17b8a214cbbd06ac69459bf988897e299c55470de4984c0",
"plain":"A flat negative based on this person's own use and on watching others: no benefit where a joint itself is damaged. No dose, no duration and no description of the damage, but a firm no-effect account from someone who tried it, carried at the same weight as the positive ones.",
"quote_sha256":"9c2b0b12855026cd0e63977cb5bf44581a0f550a154174610a242cd6a3e97e2f"
},
{
"id":"s32",
"url":"https://x.com/franchupardo/status/2082241971582579132",
"title":"Two months of the pair for knees — slight improvement, sleep and heart-rate variability disrupted until stopping (anecdotal, X, 2026-07-28)",
"quote":"I used BPC-157 and TB-500 for my knees for two months. I noticed a slight improvement, but it really messed with my sleep... once I stopped taking them, my sleep and HRV went back to normal.",
"_id":"w_y6rfenz8",
"_ts":"2026-08-04T19:36:52.768Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:52.768Z",
"claim_ids": [],
"prev":"50b34edf3842fc49a17b8a214cbbd06ac69459bf988897e299c55470de4984c0",
"hash":"790fb70c4c1740612a6005067a6594bbbd4aa26b16d609c46e10cfd33298550a",
"plain":"Two months, knees, slight benefit at best, and a downside that outweighed it: disrupted sleep and heart-rate variability, both returning to normal after stopping. Stopping and seeing the effect reverse is about the closest a single person can get to a controlled test.",
"quote_sha256":"2f275d48732d82519f9183b3085adc7b4da6d0ea99c0cb8ade37ef16bc11196c"
},
{
"id":"s33",
"url":"https://x.com/NewsAsset/status/2080378902984458706",
"title":"L5/S1 herniation, BPC-157 alone and deliberately unpaired, 90% pain reduction in two weeks (anecdotal, X, 2026-07-23)",
"quote":"I took it for my L5/S1 herniated disc and it didn't take months to get better like before. It took 2 weeks to reduce the pain by 90%. Just BPC-157. I didn't pair it with TB500",
"_id":"w_bwfwmq3b",
"_ts":"2026-08-04T19:36:52.998Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:52.998Z",
"claim_ids": [],
"prev":"790fb70c4c1740612a6005067a6594bbbd4aa26b16d609c46e10cfd33298550a",
"hash":"95718866443645f67b95cbd4c7bc4a87b133bd1220560099a0e81cd819a153f0",
"plain":"Unusually, this person used one compound on its own and says so explicitly, reporting a large fast improvement against their own slower recovery before. Still one person, no imaging, and a disc that may have been settling anyway.",
"quote_sha256":"f532acdd9fe7c54f9b8475aba6da9bb67fb8f8ac4cfadd47f5de317b2b67365c"
},
{
"id":"s34",
"url":"https://x.com/derek_j_scv/status/2056494210963107983",
"title":"BPC-157 worked on a wrist and did nothing for the same person's herniated disc (anecdotal, X, 2026-05-18)",
"quote":"I have a herniated disc. BPC157 healed the ligaments and tendon damage in my wrist. Did nothing for my disc. It only works on skeletal muscle, ligaments and tendons.",
"_id":"w_rteq8i1p",
"_ts":"2026-08-04T19:36:53.267Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:53.267Z",
"claim_ids": [],
"prev":"95718866443645f67b95cbd4c7bc4a87b133bd1220560099a0e81cd819a153f0",
"hash":"613e441f3e31362d7cdd42c698f618ae45d28f001a0883d8556f23b294bf8476",
"plain":"Same person, same compound, two different tissues, opposite outcomes — a wrist that healed and a disc that did not, with their explanation of why being their own theory. The observed split is the part worth keeping, and it argues against expecting much at the disc.",
"quote_sha256":"d43891b744686ea1d510ea12a6af3003757ebff6d947f8d6d0a9964dd0edb4cc"
},
{
"id":"s35",
"url":"https://x.com/NICKELL11b/status/2049997364883030236",
"title":"A week of BPC-157 to avoid neck surgery, surgery happened anyway (anecdotal, X, 2026-04-30)",
"quote":"I've never used any of these other than BPC 157 for a week straight.. I was trying to avoid having neck surgery, but it didn't work out that way.",
"_id":"w_xw1zj4po",
"_ts":"2026-08-04T19:36:53.533Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:53.533Z",
"claim_ids": [],
"prev":"613e441f3e31362d7cdd42c698f618ae45d28f001a0883d8556f23b294bf8476",
"hash":"760f158904914ad813fcecf5e0fc0a04bed98ad3b3dea062863a586e09b42905",
"plain":"One week of use, then the neck surgery went ahead anyway. A week is short enough that this barely tests anything, which is itself the point, since the failed accounts often involve far shorter runs than the successful ones describe.",
"quote_sha256":"09ae9155009bea36fe38458f37d60194214b0e71225a340d2a14b4509318b1f4"
},
{
"id":"s36",
"url":"https://x.com/PeptideRookie/status/2043371104731910313",
"title":"One of the two did nothing for a back injury, the other cleared it in five days (anecdotal, X, 2026-04-12)",
"quote":"You might need TB500. I used one for a back injury and it did nothing, switched to the other and it was gone within 5 days.",
"_id":"w_e00agzg9",
"_ts":"2026-08-04T19:36:53.765Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:53.765Z",
"claim_ids": [],
"prev":"760f158904914ad813fcecf5e0fc0a04bed98ad3b3dea062863a586e09b42905",
"hash":"bdd74bb90baa851b3e5a666ac4572c385d52951bf1e2f6bc9095b177db28f828",
"plain":"Two compounds tried one after the other on the same back injury: the first did nothing, the second cleared it in five days. Which was which is never said, so it supports the idea that the two are not interchangeable without saying which to reach for.",
"quote_sha256":"8b0b427a4655c25f6f7ffd232f70b846a80f0d9b8ba3fa58918ef749f4e6ad1d"
},
{
"id":"s37",
"url":"https://x.com/AhaSahhDude/status/2027919309620609260",
"title":"Oral BPC-157 capsules did not help a back problem (anecdotal, X, 2026-03-01)",
"quote":"Can you give me more details about the BPC-157? I've only taken it over capsule the injections weren't available then. Didn't help my back but I'd be curious if the injections would now.",
"_id":"w_w3piz3x7",
"_ts":"2026-08-04T19:36:54.019Z",
"type":"source",
"accessed_at":"2026-08-04T19:36:54.019Z",
"claim_ids": [],
"prev":"bdd74bb90baa851b3e5a666ac4572c385d52951bf1e2f6bc9095b177db28f828",
"hash":"30bf3ac176b4777af21c7026e37c75a0302c116621d93d544080a431ba592175",
"plain":"Capsules by mouth rather than injection, and no benefit for the back. How it is taken is the open variable running under almost every account here, and this person raises it themselves as the thing they never got to test.",
"quote_sha256":"b4b71d464e4bb7aea6756f2c2dba4e1582580fbecc65db1f0ce3d3996edb429c"
}
],
"claims": [
{
"id":"c1",
"text":"The disc is the body's largest avascular structure and repairs poorly on its own, which is the central obstacle any disc-recovery strategy must overcome.",
"tier":"mechanistic",
"source_ids": [
"s1"
],
"why_material":"The bottleneck every arm of the stack is trying to address."
},
{
"id":"c2",
"text":"The body already removes most herniations: ~67% resorb spontaneously via a macrophage- and blood-vessel-driven process, so recovery means supporting an existing mechanism, not forcing a new one.",
"tier":"human",
"source_ids": [
"s2",
"s3"
],
"why_material":"The stack works with the body's own regenerative process."
},
{
"id":"c3",
"text":"Body weight is a modifiable driver: overweight and obesity raise the odds of sciatica and disc herniation, making load reduction the one lever a person directly controls.",
"tier":"human",
"source_ids": [
"s4"
],
"why_material":"Justifies the unload-the-spine arm."
},
{
"id":"c4",
"text":"TNF-alpha and IL-1beta drive both disc degeneration and the inflammatory nerve pain of a herniation, making the inflammatory signal a shared target.",
"tier":"mechanistic",
"source_ids": [
"s5"
],
"why_material":"Justifies calming the nerve/inflammation rather than only masking pain."
},
{
"id":"c5",
"text":"A human meta-analysis found stem-cell injection may reduce discogenic pain and disability, the first real human signal that the disc is a regeneration target - though still small and early.",
"tier":"human",
"source_ids": [
"s6"
],
"why_material":"Anchors the regenerative premise in real, if limited, human data."
}
],
"widgets": [
{
"type":"stat",
"value":"66.66%",
"label":"of herniated discs shrank on their own, pooled across 11 cohort studies of people managed without surgery"
},
{
"type":"stat",
"value":"0.72",
"label":"hazard ratio for a new back-pain episode in the walking group against no treatment, 701 adults"
},
{
"type":"stat",
"value":"208 vs 112",
"label":"median days before back pain returned, walking programme against no treatment"
},
{
"type":"stat",
"value":"0",
"label":"extra benefit measured when BPC-157 and TB-500 were given together instead of alone, 32 rats, 8 per arm"
},
{
"type":"stat",
"value":"1.78",
"label":"odds of disc degeneration per unit of genetically predicted television time, the largest lifestyle factor across 20 pooled studies"
},
{
"type":"stat",
"value":"1.21x",
"label":"vertebral fracture risk added by each successive epidural steroid injection, 3,000 injected vs 3,000 matched controls"
}
],
"type":"article",
"updated":"2026-10-08T11:33:25.994Z",
"version":1,
"hash":"1875fd11dda758a08a638f64f1f5504fae6d461687297e6d11a33be9cc01b2d8",
"styling": {
"scope":"shared",
"how":"no value on the page is set by hand: each comes from this theme, and each theme value becomes the CSS variable named beside it. PATCH http://google-preview.miscsubjects.com/api/jarticles/theme changes them.",
"widget_style": {
"what":"every widget may carry style: {…}; these are the only keys it reads",
"rotate":"degrees, a number",
"offset_x":"pixels, a number",
"offset_y":"pixels, a number",
"pulse":"true to pulse"
},
"theme": {
"color": {
"page_bg":"#f5f5f7",
"sheet_bg":"#ffffff",
"ink":"#1d1d1f",
"soft":"#424245",
"muted":"#6e6e73",
"dim":"#86868b",
"line":"#d2d2d7",
"accent":"#0071e3",
"accent_soft":"rgba(0,113,227,0.08)",
"link":"#0066cc",
"selection":"rgba(0,113,227,0.18)",
"widget_bg":"#f5f5f7",
"widget_border":"#d2d2d7",
"card_bg":"#ffffff",
"code_bg":"#f5f5f7",
"json_bg":"#161b19",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#928d7e",
"json_punct":"#6b6759",
"json_bar":"#0e1512",
"kind_badge_bg":"#0e6e60",
"kind_badge_ink":"#ffffff"
},
"color_dark": {
"page_bg":"#000000",
"sheet_bg":"#1d1d1f",
"ink":"#f5f5f7",
"soft":"#d2d2d7",
"muted":"#a1a1a6",
"dim":"#86868b",
"line":"#424245",
"accent":"#2997ff",
"accent_soft":"rgba(41,151,255,0.12)",
"link":"#2997ff",
"selection":"rgba(41,151,255,0.25)",
"widget_bg":"#2c2c2e",
"widget_border":"#424245",
"card_bg":"#1d1d1f",
"code_bg":"#2c2c2e",
"json_bg":"#0a0d0c",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#757062",
"json_punct":"#5d665f",
"json_bar":"#060807",
"kind_badge_bg":"#4fc1ab",
"kind_badge_ink":"#0b0f0d"
},
"font": {
"display":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"body":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"mono":"ui-monospace,SFMono-Regular,\"SF Mono\",Menlo,Consolas,monospace",
"google_fonts":""
},
"size": {
"body":"17px",
"small":"17px",
"eye":"17px",
"lead":"17px",
"h1":"52px",
"h2":"34px",
"h3":"22px",
"byline":"17px",
"h1_measure":"none",
"code":"17px",
"json":"17px",
"widget_title":"17px"
},
"leading": {
"body":"1.7",
"head":"1.18",
"lead":"1.5",
"json":"1.6"
},
"weight": {
"display":"700",
"head":"700",
"body":"400",
"strong":"700",
"eye":"700"
},
"tracking": {
"eye":"0.14em",
"display":"-0.03em",
"body":"-0.006em",
"badge":"0.08em"
},
"layout": {
"sheet_width":"1000px",
"text_width":"880px",
"gutter":"16px",
"sheet_padding":"56px 64px 64px",
"sheet_padding_mobile":"24px 18px 40px",
"sheet_margin":"28px auto 72px",
"block_gap":"1.15em",
"widget_gap":"28px",
"grid_gap":"14px"
},
"border": {
"sheet":"0px solid",
"sheet_radius":"30px",
"widget":"1px solid",
"widget_radius":"24px",
"card_radius":"24px",
"badge_radius":"999px",
"rule":"1px solid",
"code_radius":"18px",
"accent_bar":"3px"
},
"shadow": {
"sheet":"0 1px 1px rgba(0,0,0,.02),0 6px 26px rgba(0,0,0,.05)",
"widget":"none",
"card_hover":"0 10px 28px -16px rgba(28,27,23,0.35)"
},
"motion": {
"hover":"160ms ease"
}
}
},
"page":"http://google-preview.miscsubjects.com/a/the-disc-stack",
"json":"http://google-preview.miscsubjects.com/a/the-disc-stack.json",
"markdown":"http://google-preview.miscsubjects.com/a/the-disc-stack.md",
"theme":"http://google-preview.miscsubjects.com/article-theme.json",
"calls": [
{
"what":"this article as a page (no key)",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/a/the-disc-stack",
"headers": {}
},
{
"what":"this article as its object (no key)",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/a/the-disc-stack.json",
"headers": {}
},
{
"what":"this article as Markdown (no key)",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/a/the-disc-stack.md",
"headers": {}
},
{
"what":"the object with its hash, drafts too",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/api/jarticles/the-disc-stack",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"one piece and that piece’s hash",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/api/jarticles/the-disc-stack/at?path=facts",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"grep: every key or value that matches, with the path to change it",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/api/jarticles/the-disc-stack/grep?q=owner",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"change pieces (set, merge, delete, append, insert, move); if-match is the hash",
"method":"PATCH",
"url":"http://google-preview.miscsubjects.com/api/jarticles/the-disc-stack",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash from the read>"
},
"body": {
"ops": [
{
"op":"set",
"path":"facts.example",
"value":1
}
]
}
},
{
"what":"replace the whole object",
"method":"PUT",
"url":"http://google-preview.miscsubjects.com/api/jarticles/the-disc-stack",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash>"
},
"body": {
"slug":"the-disc-stack",
"title":"…"
}
},
{
"what":"fetch every source, hash what came back and check the quote is in it",
"method":"POST",
"url":"http://google-preview.miscsubjects.com/api/jarticles/the-disc-stack/verify",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {}
},
{
"what":"an Obsidian-style command",
"method":"POST",
"url":"http://google-preview.miscsubjects.com/api/jarticles/cli",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {
"command":"backlinks",
"file":"the-disc-stack"
}
}
]
}
